Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells

International Journal of Cancer

Volumn 101, Issue 1, 2002, Pages 11-16

  Scotlandi, Katia ^a   Avnet, Sofia ^a   Benini, Stefania ^a   Manara, Maria Cristina ^a   Serra, Massimo ^a   Cerisano, Vanessa ^a   Perdichizzi, Stefania ^a   Lollini, Pier Luigi ^b   De Giovanni, Carla ^b   Landuzzi, Lorena ^c   Picci, Piero ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Apoptosis; Chemosensitivity; Dominant negative mutant; Ewing's sarcoma; Insulin like growth factor I; Nude mice; Tumorigenesis

Indexed keywords

DOXORUBICIN; RECEPTOR SUBUNIT; SOMATOMEDIN C RECEPTOR;

ALPHA CHAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOIKIS; APOPTOSIS; ARTICLE; BETA CHAIN; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; EWING SARCOMA; FEMALE; METASTASIS; METASTASIS POTENTIAL; MOUSE; MOUSE MUTANT; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL SURVIVAL; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; RECEPTOR, IGF TYPE 1; SARCOMA, EWING'S; SURVIVAL RATE; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036722799     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10537     Document Type: Article

References (38)

1. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy
2. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II
3. Ewing's tumors with primary lung metastases: Survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients
4. Neoadjuvant chemotherapy for Ewing's sarcoma of bone. No benefit observed after adding iphosphamide and etoposide to vincristine, actinomycin, cyclophosphamide and doxorubicin in the maintenance phase. Results of two sequential studies
5. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study
6. The IGF-I receptor in normal and abnormal growth
7. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target
8. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice
9. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells
10. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor
11. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptors are nontumorigenic and induce regression of wild-type tumors
12. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor I receptor
13. Blockade of the type 1 somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
14. cdc2
15. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor receptor mutant
16. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis
17. Dominant negative mutant of the insulin-like growth factor-1 receptor inhibits the adhesion, invasion and metastases of breast cancer
18. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor
19. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors
20. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor
21. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R
22. Mutant IGF-I receptors as dominant negatives for growth and transformation
23. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect
24. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor
25. Intracellular association of a mutant insulin-like growth factor receptor with endogenous receptors
26. Calcium phosphate mediated gene transfer into established cell lines
27. Role of cell shape in growth control
28. Insulin-like growth factor-I-mediated survival from anoikis: Role of cell aggregation and focal adhesion kinase
29. Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion
30. Basis for the acquisition of malignant potential by mouse cells cultivated in vitro
31. Murine model for skeletal metastases of Ewing's sarcoma
32. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts
33. The IGF-I receptor in cell growth, transformation and apoptosis
34. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis
35. Insulin-like growth factor 1 receptor overexpression mediates cellular resistance and local breast cancer recurrence after lumpectomy and radiation
36. Effect of the insulin-like growth factor 1 receptor on ionizing radiation-induced cell death in mouse embryo fibroblast
37. Insulin-like growth factor I (IGF-I) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs
38. Effectiveness of insulin-like growth factor receptor I antisense strategy against Ewing's sarcoma cells